The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events

J Thromb Haemost. 2020 May;18(5):1087-1093. doi: 10.1111/jth.14771. Epub 2020 Mar 20.

Abstract

Background: Recently, our group has reported a 13-bp deletion in a poly(T)-track in the F8 intron 13 as the causative variant in approximately 6% of all cases of mild haemophilia A (HA) in France. The systematic screening of mild HA patients for this deletion identified individuals carrying deletions from 9 to 14-bp in the same region.

Aims: To demonstrate that these highly prevalent deletions could result from a recurrent molecular mechanism and to determine the clinical significance of deletions other than 13-bp in size.

Methods: Haplotype analysis using five polymorphic markers was performed in 71 unrelated French mild hemophilia A patients. Minigene analysis was performed to study the splicing impact of deletions from 1 to 14-bp.

Results: A peculiar haplotype (H1) was identified in 22.5% of patients carrying the 13-bp deletion. Haplotypes differing from H1 only for the two most distal markers were found in more than the half of patients. These results confirmed the founder effect origin for the 13-bp deletion. However, the 9 patients carrying other sizes of deletion had a different haplotype suggesting that these deletions arose independently. Supporting the recurrent mechanism hypothesis, similar deletions were also found in 3/19 genetically unresolved mild Canadian patients. In vitro splicing analysis confirmed that deletions larger than 9-bp had a deleterious impact on splicing of F8 transcript.

Conclusion: We demonstrated that the poly(T)-track in F8 intron 13 is a deletion hotspot. We recommend that deletions in this region should be specifically investigated in all genetically unresolved mild HA patients.

Keywords: Alu element; founder effect; haemophilia A; haplotype; recurrent mechanism.

MeSH terms

  • Canada
  • DNA Mutational Analysis
  • Factor VIII / genetics
  • Founder Effect
  • France / epidemiology
  • Hemophilia A* / diagnosis
  • Hemophilia A* / epidemiology
  • Hemophilia A* / genetics
  • Humans
  • Introns
  • Mutation

Substances

  • Factor VIII